Christopher Richard Anzalone, Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 52,062 shares at $68.85 ($3.5M) on 2025-12-22, disclosed to the SEC on 2025-12-23.
Scheduled sale ($3.5M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $66.67 | 3,979 | $265K | 7.5% |
| 2 | $66.67 | 3,979 | $265K | 7.5% |
| 3 | $68.01 | 8,147 | $554K | 15.6% |
| 4 | $68.01 | 8,147 | $554K | 15.6% |
| 5 | $68.48 | 1,319 | $90K | 2.6% |
| 6 | $68.48 | 1,319 |
| $90K |
| 2.6% |
| 7 | $68.33 | 10,012 | $684K | 19.3% |
| 8 | $68.33 | 10,012 | $684K | 19.3% |
| 9 | $68.85 | 2,574 | $177K | 5.0% |
| 10 | $68.85 | 2,574 | $177K | 5.0% |
| Total | $68.04 avg | 52,062 | $3.5M | 100% |
| Filing → |
| ARWR | SELL | 2025-12-19 | $10.9M | — | Filing → |
| ARWR | SELL | 2025-12-16 | $24.6M | — | Filing → |
| ARWR | SELL | 2025-04-11 | $1.9M | — | Filing → |